- Conditions
- CHF, COPD
- Interventions
- Technology-assisted care transition intervention, Active attention control
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Hines, Illinois • Iowa City, Iowa + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 13,445
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronary Artery Disease, Angina Pectoris
- Interventions
- Ranolazine, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,651 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 74 more
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- ipilimumab, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Inflammatory Bowel Diseases, Irritable Bowel Syndrome, Ulcerative Colitis, Crohn Disease, Indeterminate Colitis, Chronic Diarrhea, Celiac Disease, Diverticulitis, Abdominal Pain, Distension, Weight Loss, Food Intolerance, Constipation
- Interventions
- Stool collection
- Diagnostic Test
- Lead sponsor
- DiaSorin Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 13
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Mission Hills, California + 10 more
- Conditions
- Chronic Nonmalignant Pain, Pain, Intractable, Pain, Chronic
- Interventions
- Flowonix Prometra® II Programmable Infusion System, Pain Medicine
- Device · Drug
- Lead sponsor
- Evolve Restorative Center
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Santa Rosa, California
- Conditions
- Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
- Interventions
- ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg, GLASSIA 120 mg/kg, Human Albumin 2%
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 14
- States / cities
- Peoria, Arizona • Newport Beach, California • Kissimmee, Florida + 11 more
- Conditions
- Chronic Pain
- Interventions
- Cognitive Behavioral Therapy (CBT), Hypnotic Cognitive Therapy (HYP-CT), Mindfulness-Based Cognitive Therapy (MBCT)
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Seattle, Washington • Tacoma, Washington
- Conditions
- Chronic Migraine
- Interventions
- HD-tDCS Active Protocol, HD-tDCS Sham Protocol
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hyperphosphatemia, Chronic Kidney Disease
- Interventions
- K2CG chewing gum
- Other
- Lead sponsor
- Denver Nephrologists, P.C.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Diabetes, End Stage Renal Disease
- Interventions
- EchoMark/EchoSure, Standard of Care
- Device · Procedure
- Lead sponsor
- Sonavex, Inc.
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 21
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
- Conditions
- Chronic Venous Disease
- Interventions
- Indocyanine Green near infrared fluorescence imaging, advanced pneumatic compression, Duplex ultrasound, compression wrap
- Combination Product · Device · Diagnostic Test
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Disease
- Interventions
- baa nnilah
- Behavioral
- Lead sponsor
- Montana State University
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Crow Agency, Montana
- Conditions
- Lumbar Spinal Stenosis
- Interventions
- Superion™ IDS device
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2041
- U.S. locations
- 23
- States / cities
- Carlsbad, California • Larkspur, California • Rancho Mirage, California + 20 more
- Conditions
- Chronic Hepatitis b, Viremia
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Interventions
- Best Practice, Biomarker Analysis, Biospecimen Collection, Questionnaire Administration, Ruxolitinib
- Other · Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Chronic Plantar Fasciitis
- Interventions
- Intense Therapeutic Ultrasound Treatment - ITU
- Device
- Lead sponsor
- Guided Therapy Systems
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Post-COVID Conditions, Obesity
- Interventions
- 12-weeks of Weight Loss, 12-weeks of Weight Stability
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Up to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • San Antonio, Texas
- Conditions
- Migraine With Aura, Migraine Without Aura, Chronic Migraine
- Interventions
- milnacipran
- Drug
- Lead sponsor
- California Medical Clinic for Headache
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration, WEE1 Inhibitor AZD1775
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Vitamin D Deficiency
- Interventions
- cholecalciferol
- Dietary Supplement
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Chronic Sinusitis
- Interventions
- PROPEL Mini Sinus Implant., Sinus Surgery alone, Propel Nova Sinus Implant
- Device · Procedure
- Lead sponsor
- Intersect ENT
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Sacramento, California • Torrance, California • Norwalk, Connecticut + 7 more
- Conditions
- Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Fanconi Anemia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Monrovia, California
- Conditions
- Chronic Hand Eczema (CHE)
- Interventions
- Ruxolitinib cream, Vehicle
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Huntington Beach, California • Westminster, California + 8 more
- Conditions
- Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia
- Interventions
- BMS-214662, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Houston, Texas